Evidence map›Paper›PMID 40641929›Full record

ReviewFrontiers in oncology2025

Young lung cancer: from diagnosis to survivorship.

Narjust Florez, Lauren Kiel, Rebekah Kaufman, Jaclyn LoPiccolo, Biagio Ricciuti, Angela Morabito, Olayinka Fakorede, Courtney Mantz, Coral Olazagasti, Nishwant Swami and 7 more

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Narjust FlorezLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Lauren KielLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Rebekah KaufmanLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Jaclyn LoPiccoloLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Biagio RicciutiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Angela MorabitoLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Olayinka FakoredeHarvard Medical School, Boston, MA, United States.
Courtney MantzLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Coral OlazagastiSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States.
Nishwant SwamiDepartment of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, United States.
Duaa KananUniversity of Illinois College of Medicine Peoria, Peoria, IL, United States.
Laura AlderDuke Cancer Center, Duke University School of Medicine, Durham, NC, United States.
Arthi SridharDivision of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX, United States.
Cristiane Decat BergerotCentro de Câncer de Brasília, Instituto Unity de Ensino e Pesquisa, Grupo Oncoclinicas, Brasília, Brazil.
Bianca ByeYoung Lung Cancer Initiative, Raleigh, NC, United States.
Ana I VelazquezDepartment of Medicine, University of California San Francisco, San Francisco, CA, United States.
Alice T ShawLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Young patients with lung cancer represent a distinct population, with unique disease and treatment-related characteristics, as well as psychosocial and survivorship needs. Nevertheless, this population remains vastly understudied. Methods: We review the unique clinicopathological characteristics and needs of young patients with lung cancer, including topics such as incidence rates, diagnostic challenges, genomics, treatment patterns and outcomes, psychosocial needs, fertility and sexual health, and palliative care. We discuss emerging and understudied data, provide recommendations on aspects in which future research is warranted, and advocate for actionable strategies that multi-disciplinary healthcare teams may adopt to provide more personalized and equitable care. Results: Though epidemiological trends suggest an overall decrease in lung cancer incidence among all age groups, recent increasing incidences have been reported among certain young populations in the U.S., as well as among Hispanic women and women in certain European countries. Young patients are significantly more likely to be female or Asian/Pacific Islander, have no tobacco use history, metastasis to the brain, and a higher frequency of somatic mutations or rearrangements. Diagnostic delays pose a considerable concern to young patients with lung cancer and may contribute to how these patients are more likely to be diagnosed with advanced disease than their older counterparts. However, young patients demonstrate improved survival compared to older patients, underscoring the importance of survivorship care. Young patients are more likely to be diagnosed at a disruptive time in their lives, rendering them with distinct psychosocial needs and financial toxicity. Future data on treatment-related effects on fertility and sexual health for young patients is warranted, as is the data related to complementary medicine use. Training in palliative care and promoting a positive attitude towards supportive care is also essential. Conclusions: Young patients with lung cancer represent a distinct patient population, necessitating disease management that is markedly different from that of older patients with lung cancer. Future research, some of which are highlighted by this Review, will aid in elucidating risk factors, survival rates, and clinical, genomic, and histopathological characteristics of young-onset lung cancer to improve screening, early detection, prevention, and treatment of this understudied population.

Indexed as

diagnostic delayslung cancerpsychosocialtargeted therapyyoung patients

Identifiers

PMID40641929
PMCPMC12240950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.